The Effect of CoQ10 Administration on Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by:
University of Shizuoka
ClinicalTrials.gov Identifier:
NCT00307996
First received: March 27, 2006
Last updated: NA
Last verified: March 2006
History: No changes posted
  Purpose

The purpose of this study is to examine whether CoQ10 administration is effective as an antioxidant in hemodialysis patients.


Condition Intervention Phase
Chronic Renal Failure
Hemodialysis
Drug: Coenzyme Q10 (drug)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients

Resource links provided by NLM:


Further study details as provided by University of Shizuoka:

Primary Outcome Measures:
  • Oxidative protein concentration at 6 month
  • Antioxidant capacity at 6 month

Estimated Enrollment: 40
Study Start Date: March 2004
Estimated Study Completion Date: December 2004
Detailed Description:

Oxidative stress has been recognized as a potential risk factor for such complications as atherosclerosis in hemodialysis patients. This study investigates whether CoQ10 administration is effective for protecting oxidative stress in hemodialysis patients. The subjects were recruited from day-time hemodialysis patients in Iwata City Hospital. 100 mg CoQ10 was administered every HD for 6 months. Several oxidative and antioxidative markers were measured in plasma at pre, 1, 3, 6 months and after washout.

  Eligibility

Ages Eligible for Study:   up to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hemodialysis for at least 6 months

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00307996

Locations
Japan
Iwata City Hospital
Iwata, Shizuoka, Japan, 438-8550
Sponsors and Collaborators
University of Shizuoka
Investigators
Study Chair: Hiromichi Kumagai, MD University of Shizuoka
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00307996     History of Changes
Other Study ID Numbers: CT2006001
Study First Received: March 27, 2006
Last Updated: March 27, 2006
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by University of Shizuoka:
CoQ10
hemodialysis
oxidative marker
antioxidant

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Coenzyme Q10
Ubiquinone
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Vitamins

ClinicalTrials.gov processed this record on August 21, 2014